These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 6235888)

  • 1. Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.
    Kerle D; Williams G; Ware H; Bloom SR
    Br Med J (Clin Res Ed); 1984 Aug; 289(6443):468-9. PubMed ID: 6235888
    [No Abstract]   [Full Text] [Related]  

  • 2. Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone.
    Ahmed SR; Shalet SM; Grant J; Howell A; Blacklock NJ
    Br Med J (Clin Res Ed); 1984 Sep; 289(6448):831. PubMed ID: 6236870
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostatic cancer: treatment with long-acting LHRH analogue.
    Williams G; Allen JM; O'Shea JP; Mashiter K; Doble A; Bloom SR
    Br J Urol; 1983 Dec; 55(6):743-6. PubMed ID: 6228283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long term treatment with luteinising hormone releasing hormone agonists and maintenance of serum testosterone to castration concentrations.
    Labrie F; Dupont A; Belanger A; Lachance R; Giguere M
    Br Med J (Clin Res Ed); 1985 Aug; 291(6492):369-70. PubMed ID: 3926197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced carcinoma of the prostate: treatment with a gonadotrophin releasing hormone agonist.
    Allen JM; O'Shea JP; Mashiter K; Williams G; Bloom SR
    Br Med J (Clin Res Ed); 1983 May; 286(6378):1607-9. PubMed ID: 6221774
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biodegradable polymer luteinising hormone releasing hormone analogue for prostatic cancer: use of a new peptide delivery system.
    Williams G; Kerle D; Griffin S; Dunlop H; Bloom SR
    Br Med J (Clin Res Ed); 1984 Dec; 289(6458):1580-1. PubMed ID: 6239674
    [No Abstract]   [Full Text] [Related]  

  • 7. LHRH.
    Glode LM; Smith JA
    JAMA; 1985 Jul; 254(4):506-7. PubMed ID: 3892064
    [No Abstract]   [Full Text] [Related]  

  • 8. Oestrogen pre-treatment abolishes luteinising hormone-releasing hormone testosterone stimulation.
    Kreis W; Ahmann FR; Jordan VC; de Haan H; Scott M
    Br J Urol; 1988 Oct; 62(4):352-4. PubMed ID: 2973364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In regard to Padula et al., normalization of serum testosterone levels in patients treated with neoadjuvant hormonal therapy and three-dimensional conformal radiotherapy for prostate cancer. IJROBP 2002;52: 439-443.
    Dearnaley DP; Norman AR; Shahidi M
    Int J Radiat Oncol Biol Phys; 2002 Nov; 54(3):981; author reply 981. PubMed ID: 12377353
    [No Abstract]   [Full Text] [Related]  

  • 10. Therapeutic potential of the LHRH agonist, ICI 118630, in the treatment of advanced prostatic carcinoma.
    Walker KJ; Nicholson RI; Turkes AO; Turkes A; Griffiths K; Robinson M; Crispin Z; Dris S
    Lancet; 1983 Aug; 2(8347):413-5. PubMed ID: 6135908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment with D-Trp-6-LHRH. Plasma levels and gonadotropic response].
    Lahlou N; Duchier J; Feinstein MC; Mauvernay RY; Roger M; Schally AV
    Pathol Biol (Paris); 1984 Oct; 32(8):906-8. PubMed ID: 6209605
    [No Abstract]   [Full Text] [Related]  

  • 12. Results of a Dutch Phase II trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer.
    Debruyne FM; Karthaus HF; Schröder FH; de Voogt HJ; de Jong FH; Klijn JG
    Prog Clin Biol Res; 1985; 185A():251-70. PubMed ID: 3929265
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment with gonadotrophin releasing hormone analogue in advanced prostatic cancer.
    Waxman JH; Wass JA; Hendry WF; Whitfield HN; Besser GM; Malpas JS; Oliver RT
    Br Med J (Clin Res Ed); 1983 Apr; 286(6374):1309-12. PubMed ID: 6404441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine and clinical effects of leuprolide in prostatic cancer.
    Vance MA; Smith JA
    Clin Pharmacol Ther; 1984 Sep; 36(3):350-4. PubMed ID: 6432399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.
    Guess B; Scholz M
    J Urol; 2001 May; 165(5):1644-5. PubMed ID: 11345950
    [No Abstract]   [Full Text] [Related]  

  • 16. Combined treatment with ketoconazole and luteinising hormone releasing hormone analogue: a novel approach to resistant progressive prostatic cancer.
    Allen JM; Kerle DJ; Ware H; Doble A; Williams G; Bloom SR
    Br Med J (Clin Res Ed); 1983 Dec; 287(6407):1766. PubMed ID: 6315133
    [No Abstract]   [Full Text] [Related]  

  • 17. Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach?
    Borgmann V; Hardt W; Schmidt-Gollwitzer M; Adenauer H; Nagel R
    Lancet; 1982 May; 1(8281):1097-9. PubMed ID: 6122893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sustained impairment of pituitary and testicular function in prostatic cancer patients treated with a depot form of a GnRH agonist.
    Rolandi E; Franceschini R; Giberti C; Brancadoro T; Martorana G; Barreca T
    Horm Res; 1988; 30(1):22-5. PubMed ID: 2975631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Failure to maintain the suppressed level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer.
    Kinouchi T; Maeda O; Ono Y; Meguro N; Kuroda M; Usami M
    Int J Urol; 2002 Jun; 9(6):359-61. PubMed ID: 12110102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-acting gonadotropin-releasing hormone implant to maintain medical castration for two years in men with prostate cancer.
    Spitz IM; Chertin B; Lindenberg T; Farkas A
    N Engl J Med; 1999 May; 340(18):1439. PubMed ID: 10328706
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.